Rossignol P, Dobre D, McMurray JJ, Swedberg K, Krum H, van Veldhuisen DJ, Shi H, Messig M, Vincent J, Girerd N et al (2014) Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF). Circ Heart Fail 7:51–58. https://doi.org/10.1161/circheartfailure.113.000792

Article  PubMed  CAS  Google Scholar 

Vardeny O, Wu DH, Desai A, Rossignol P, Zannad F, Pitt B, Solomon SD (2012) Influence of baseline and worsening renal function on efficacy of spironolactone in patients With severe heart failure: insights from RALES (Randomized Aldactone Evaluation Study). J Am Coll Cardiol 60:2082–2089. https://doi.org/10.1016/j.jacc.2012.07.048

Article  PubMed  CAS  Google Scholar 

Beldhuis IE, Myhre PL, Bristow M, Claggett B, Damman K, Fang JC, Fleg JL, McKinlay S, Lewis EF, O’Meara E et al (2021) Spironolactone in patients with heart failure, preserved ejection fraction, and worsening renal function. J Am Coll Cardiol 77:1211–1221. https://doi.org/10.1016/j.jacc.2020.12.057

Article  PubMed  CAS  Google Scholar 

Rossignol P, Hernandez AF, Solomon SD, Zannad F (2019) Heart failure drug treatment. Lancet 393:1034–1044. https://doi.org/10.1016/s0140-6736(18)31808-7

Article  PubMed  CAS  Google Scholar 

Cleland JGF, Ferreira JP, Mariottoni B, Pellicori P, Cuthbert J, Verdonschot JAJ, Petutschnigg J, Ahmed FZ, Cosmi F, Brunner La Rocca HP et al (2020) The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart “OMics” in AGEing (HOMAGE) randomized clinical trial. Eur Heart J. https://doi.org/10.1093/eurheartj/ehaa758

Article  PubMed  PubMed Central  Google Scholar 

Pellicori P, Ferreira JP, Mariottoni B, Brunner-La Rocca HP, Ahmed FZ, Verdonschot J, Collier T, Cuthbert JJ, Petutschnigg J, Mujaj B et al (2020) Effects of spironolactone on serum markers of fibrosis in people at high risk of developing heart failure: rationale, design and baseline characteristics of a proof-of-concept, randomised, precision-medicine, prevention trial. The Heart OMics in AGing (HOMAGE) trial. Eur J Heart Fail. https://doi.org/10.1002/ejhf.1716

Article  PubMed  Google Scholar 

Monzo L, Ferreira JP, Cleland JGF, Pellicori P, Mariottoni B, Hazebroek MR, Collier TJ, Cuthbert JJ, Pieske B, Petutschnigg J et al (2022) Dyskalemia in people at increased risk for heart failure: findings from the heart “OMics” in AGEing (HOMAGE) trial. ESC Heart Fail. https://doi.org/10.1002/ehf2.14086

Article  PubMed  Google Scholar 

Ferreira JP, Verdonschot J, Wang P, Pizard A, Collier T, Ahmed FZ, Brunner-La-Rocca HP, Clark AL, Cosmi F, Cuthbert J et al (2021) Proteomic and mechanistic analysis of spironolactone in patients at risk for HF. JACC Heart Fail. https://doi.org/10.1016/j.jchf.2020.11.010

Article  PubMed  Google Scholar 

Ferreira JP, Rossignol P, Bakris G, Mehta C, White WB, Zannad F (2021) Blood and urine biomarkers predicting worsening kidney function in patients with Type 2 diabetes post-acute coronary syndrome: an analysis from the EXAMINE trial. Am J Nephrol 52:969–976. https://doi.org/10.1159/000519436

Article  PubMed  CAS  Google Scholar 

Ahmad T, Jackson K, Rao VS, Tang WHW, Brisco-Bacik MA, Chen HH, Felker GM, Hernandez AF, O’Connor CM, Sabbisetti VS et al (2018) Worsening renal function in patients with acute heart failure undergoing aggressive diuresis is not associated with tubular injury. Circulation 137:2016–2028. https://doi.org/10.1161/circulationaha.117.030112

Article  PubMed  PubMed Central  Google Scholar